The advent of BCR-ABL1 tyrosine kinase inhibitors has revolutionized the treatment and prognosis of chronic myeloid leukemia. Life expectancy for patients with chronic phase chronic myeloid leukemia now nears that of the healthy population; however, optimal outcomes require continuous tyrosine kinase inhibitor administration, which can impact patient quality of life. Consequently, the concept of treatment-free remission has been explored in patients achieving and sustaining a deep molecular response. Heterogeneous data exist with multiple tyrosine kinase inhibitors; however, nilotinib is currently the only therapy that has been approved by the US Food and Drug Administration for treatment-free remission. The decision to pursue treatment-free remission is one that relies heavily on both patient- and disease-related factors. Herein, we will discuss relevant considerations to be made when determining an optimal candidate for treatment-free remission.

中文翻译：

---

优化患者选择，实现无治疗缓解。

BCR-ABL1酪氨酸激酶抑制剂的出现彻底改变了慢性粒细胞白血病的治疗和预后。现在，慢性期慢性粒细胞白血病患者的预期寿命已接近健康人群的预期寿命。但是，最佳结果需要连续施用酪氨酸激酶抑制剂，这可能会影响患者的生活质量。因此，在获得并维持深分子应答的患者中，探索了无治疗缓解的概念。多种酪氨酸激酶抑制剂存在异构数据。但是，尼洛替尼是目前唯一获得美国食品和药物管理局批准的无治疗缓解的疗法。寻求无治疗缓解的决定很大程度上取决于患者和疾病相关因素。在这里